AngioDynamics Inc. (ANGO) reported its Q1 FY2026 earnings, surpassing revenue and EPS forecasts. The company achieved a revenue of $75.7 million, exceeding the forecasted $72.7 million. Earnings per share (EPS) came in at -$0.10, beating the expected -$0.12. Following the announcement, AngioDynamics’ stock rose 17.43% in premarket trading, reaching $13, signaling investor optimism.
Key Takeaways
- AngioDynamics’ Q1 FY2026 revenue grew 12.2% year-over-year.
- The company’s EPS surpassed expectations by 16.67%.
- Premarket trading saw a significant stock price increase of 17.43%.
- Strong growth reported in the med-tech segment, particularly in mechanical thrombectomy.
Company Performance
AngioDynamics demonstrated robust performance with a 12.2% increase in revenue compared to the same quarter last year. This growth was driven by substantial gains in its med-tech segment, which saw a 26.1% rise. The company’s strategic focus on product innovation and market expansion has positioned it well against competitors in the med-tech industry.
Financial Highlights
- Revenue: $75.7 million, up 12.2% year-over-year
- Med-tech revenue: $35.3 million, up 26.1%
- Gross margin: 55.3%, increased by 90 basis points
- Adjusted EBITDA: $2.2 million, compared to a loss of $152,000 in Q1 FY2025
Earnings vs. Forecast
AngioDynamics reported an EPS of -$0.10, which was better than the forecasted -$0.12, marking a surprise of 16.67%. The revenue of $75.7 million also exceeded expectations by 4.13%, showcasing the company’s ability to outperform market projections.
Market Reaction
Following the earnings announcement, AngioDynamics’ stock surged by 17.43% in premarket trading, reaching $13. This movement indicates strong investor confidence, supported by the company’s positive earnings surprise and strategic advancements. The stock’s performance aligns with its trajectory towards its 52-week high of $13.5. With a market capitalization of $454.71 million and analyst price targets ranging from $16 to $24,
Outlook & Guidance
AngioDynamics revised its FY2026 net sales guidance to $308-$313 million, reflecting a growth rate of 5-7%. The company also raised its adjusted EBITDA guidance to $6-$10 million and expects an adjusted loss per share to improve to between $0.33 and $0.23. These revisions highlight the company’s optimistic outlook for the fiscal year.
Executive Commentary
CEO Jim Clemmer stated, "We had a great first quarter. We continued to grow across all areas of our business," emphasizing the company’s strong start to the fiscal year. CFO Steve Trowbridge added, "Auryon has now delivered double-digit year-over-year growth for 17 consecutive quarters," underscoring the consistent performance of their key product.
Risks and Challenges
- Supply chain disruptions could impact production timelines and costs.
- Market saturation in certain segments may limit growth potential.
- Macroeconomic factors, such as inflation, could affect consumer spending and operational costs.
Q&A
During the earnings call, analysts inquired about the drivers behind the mechanical thrombectomy growth. The company attributed this to new customer acquisitions and increased product utilization. Questions also focused on the ongoing Ambition BTK clinical trial and investment plans for expanding the sales force, indicating investor interest in the company’s strategic initiatives.
Full transcript - AngioDynamics Inc (ANGO) Q1 2026:
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.